Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase InhibitorHiroaki Akamatsu, Nobuyuki Yamamoto, Nobuyuki Katakami et al.|JAMA Oncology|2021Cited by 185
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L StudyHirotsugu Kenmotsu, Toshiaki Takahashi, Kazushige Wakuda et al.|Journal of Thoracic Oncology|2022Cited by 158
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD. Ross Camidge, Shun Lü, Jair Bar et al.|Journal of Clinical Oncology|2024Cited by 131
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive CancerAlison M. Schram, Alexander Drilon, Kōichi Goto et al.|New England Journal of Medicine|2025Cited by 104